SECONAL SODIUM by Eli Lilly and Company is clinical pharmacology barbiturates are capable of producing all levels of cns mood alteration, from excitation to mild sedation, hypnosis, and deep coma. First approved in 1950.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
Seconal Sodium is a short-acting barbiturate injectable administered for sedation, hypnosis, and anesthesia induction. It works by depressing the central nervous system across multiple levels, from mild sedation to deep coma, with onset within 10-15 minutes and duration of 3-4 hours. It is indicated for short-term insomnia management and pre-operative sedation, though its effectiveness diminishes significantly after 2 weeks of continuous use.
This legacy product is approaching loss of exclusivity with minimal linked job openings (0), indicating a small or winding-down brand team focused on managed care and compliance rather than growth.
CLINICAL PHARMACOLOGY Barbiturates are capable of producing all levels of CNS mood alteration, from excitation to mild sedation, hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia. Barbiturates depress the sensory cortex, decrease…
Worked on SECONAL SODIUM at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career opportunities on Seconal Sodium are severely limited; the product is a legacy agent with declining commercial relevance and no linked job openings. Roles available are primarily defensive—focused on regulatory maintenance, compliance, and supply management rather than growth, innovation, or commercial advancement.